Estimating the Impact and Cost of the WHO 2010 Recommendations for Antiretroviral Therapy
In July 2010, WHO published new recommendations on providing antiretroviral therapy to adults and adolescents, including starting ART earlier, usually at a CD4 count of 350 or lower, specific regimens for first- and second-line therapies, and other recommendations. This paper estimates the potential...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | AIDS Research and Treatment |
| Online Access: | http://dx.doi.org/10.1155/2011/738271 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552254534582272 |
|---|---|
| author | John Stover Lori Bollinger Carlos Avila |
| author_facet | John Stover Lori Bollinger Carlos Avila |
| author_sort | John Stover |
| collection | DOAJ |
| description | In July 2010, WHO published new recommendations on providing antiretroviral therapy to adults and adolescents, including starting ART earlier, usually at a CD4 count of 350 or lower, specific regimens for first- and second-line therapies, and other recommendations. This paper estimates the potential impact and cost of the revised guidelines by first, calculating the number of people that would be in need of antiretroviral therapy (ART) with different eligibility criteria, and second, calculating the costs associated with the potential impact. Results indicate that switching the eligibility criterion from CD4 count <200 to <350 increases the need for ART in low- and middle-income countries (country-level) by 50% (range 34% to 70%). The costs of ART programs only to increase coverage to 80% by 2015 would be 44% more (range 29% to 63%) when switching the eligibility criterion to CD4 count <350. When testing and outreach costs are included, total costs increase by 62%, from US$26.3 billion under the previous eligibility criterion of treating those with CD4 <200 to US$42.5 billion using the revised eligibility criterion of treating those with CD4 <350. |
| format | Article |
| id | doaj-art-c4d3200c3c0542fca9827f72e6935195 |
| institution | Kabale University |
| issn | 2090-1240 2090-1259 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | AIDS Research and Treatment |
| spelling | doaj-art-c4d3200c3c0542fca9827f72e69351952025-02-03T05:59:10ZengWileyAIDS Research and Treatment2090-12402090-12592011-01-01201110.1155/2011/738271738271Estimating the Impact and Cost of the WHO 2010 Recommendations for Antiretroviral TherapyJohn Stover0Lori Bollinger1Carlos Avila2Futures Institute, 41-A New London Turnpike, Glastonbury, CT 06033, USAFutures Institute, 41-A New London Turnpike, Glastonbury, CT 06033, USAUNAIDS, Avenue Appia 20, 1211 Genève, SwitzerlandIn July 2010, WHO published new recommendations on providing antiretroviral therapy to adults and adolescents, including starting ART earlier, usually at a CD4 count of 350 or lower, specific regimens for first- and second-line therapies, and other recommendations. This paper estimates the potential impact and cost of the revised guidelines by first, calculating the number of people that would be in need of antiretroviral therapy (ART) with different eligibility criteria, and second, calculating the costs associated with the potential impact. Results indicate that switching the eligibility criterion from CD4 count <200 to <350 increases the need for ART in low- and middle-income countries (country-level) by 50% (range 34% to 70%). The costs of ART programs only to increase coverage to 80% by 2015 would be 44% more (range 29% to 63%) when switching the eligibility criterion to CD4 count <350. When testing and outreach costs are included, total costs increase by 62%, from US$26.3 billion under the previous eligibility criterion of treating those with CD4 <200 to US$42.5 billion using the revised eligibility criterion of treating those with CD4 <350.http://dx.doi.org/10.1155/2011/738271 |
| spellingShingle | John Stover Lori Bollinger Carlos Avila Estimating the Impact and Cost of the WHO 2010 Recommendations for Antiretroviral Therapy AIDS Research and Treatment |
| title | Estimating the Impact and Cost of the WHO 2010 Recommendations for Antiretroviral Therapy |
| title_full | Estimating the Impact and Cost of the WHO 2010 Recommendations for Antiretroviral Therapy |
| title_fullStr | Estimating the Impact and Cost of the WHO 2010 Recommendations for Antiretroviral Therapy |
| title_full_unstemmed | Estimating the Impact and Cost of the WHO 2010 Recommendations for Antiretroviral Therapy |
| title_short | Estimating the Impact and Cost of the WHO 2010 Recommendations for Antiretroviral Therapy |
| title_sort | estimating the impact and cost of the who 2010 recommendations for antiretroviral therapy |
| url | http://dx.doi.org/10.1155/2011/738271 |
| work_keys_str_mv | AT johnstover estimatingtheimpactandcostofthewho2010recommendationsforantiretroviraltherapy AT loribollinger estimatingtheimpactandcostofthewho2010recommendationsforantiretroviraltherapy AT carlosavila estimatingtheimpactandcostofthewho2010recommendationsforantiretroviraltherapy |